FARN: Bexmarilimab reports 45% CR in HR-MDS
FARN says its Bexmarilimab delivered 45% CR in HR-MDS and that EUR 40M raised secures funding through 2027 milestones.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.